Jennifer Linge will serve as one of three experts during an important session regarding the effects of GLP-1-based treatments on muscle health in cardiometabolic diseases, titled Great Debate: do GLP-1 analogues/GLP-1 receptor agonists (GLP-1RAs) worsen muscle loss in cardiometabolic disease? The goal of the session, as outlined by the organizers, is to understand the mechanism and clinical role of GLP-1 receptor agonists in cardiometabolic disease
doi:10.1111/bcp.12777 Simental-Menda LE, Snchez-Garca A, Linden-Torres E, Simental-Menda M
Some people have reported increased sweating and a blue stain on sweat-exposed clothing or skin
Losing weight or maintaining a healthy weight is also critical for breast cancer patients and thrivers
Patients with a personal or family history of thyroid cancer or multiple endocrine neoplasia type 2 are typically excluded from GLP-1 treatment due to safety concerns
Additionally, research suggests that people are more likely to lose weight if the drug is taken long-term
